These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8899123)

  • 1. Study provides head-to-head comparison of terazosin, finasteride.
    Am J Health Syst Pharm; 1996 Oct; 53(20):2380, 2382. PubMed ID: 8899123
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic controversies: clinical treatment of benign prostatic hyperplasia.
    Geller J; Kirchenbaum A; Lepor H; Levine AC
    J Clin Endocrinol Metab; 1995 Mar; 80(3):745-7. PubMed ID: 7533770
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of benign prostatic hyperplasia.
    Walsh PC
    N Engl J Med; 1996 Aug; 335(8):586-7. PubMed ID: 8678937
    [No Abstract]   [Full Text] [Related]  

  • 5. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination drug therapy for benign prostatic hyperplasia.
    Kreder KJ
    JAMA; 1995 Jul; 274(4):359. PubMed ID: 7541871
    [No Abstract]   [Full Text] [Related]  

  • 7. Terazosin vs finasteride for BPH.
    Zacks M
    J Fam Pract; 1996 Dec; 43(6):533. PubMed ID: 8969692
    [No Abstract]   [Full Text] [Related]  

  • 8. Medical treatment as an alternative to surgery in the management of benign prostatic hypertrophy.
    Bredin HC
    Ir Med J; 1996; 89(3):86, 88. PubMed ID: 8707527
    [No Abstract]   [Full Text] [Related]  

  • 9. What is the best medical treatment for benign prostate hyperplasia?
    Evans MF; Frank J
    Can Fam Physician; 1997 Jun; 43():1073-4. PubMed ID: 9189295
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
    Glassman DT; Chon JK; Borkowski A; Jacobs SC; Kyprianou N
    Prostate; 2001 Jan; 46(1):45-51. PubMed ID: 11170131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terazosin, finasteride, or both in benign prostatic hyperplasia.
    Kuchel GA; DuBeau CE; Resnick NM
    N Engl J Med; 1997 Jan; 336(4):293-4; author reply 294. PubMed ID: 9005317
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gonzalez CM; McVary KT
    Curr Urol Rep; 2003 Aug; 4(4):276-81. PubMed ID: 12882718
    [No Abstract]   [Full Text] [Related]  

  • 16. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
    Johnson TM; Jones K; Williford WO; Kutner MH; Issa MM; Lepor H
    J Urol; 2003 Jul; 170(1):145-8. PubMed ID: 12796667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A current review of medical therapy for benign prostatic hyperplasia.
    Brown GA; Sussman DO
    J Am Osteopath Assoc; 2004 Feb; 104(2 Suppl 2):S11-6. PubMed ID: 15038398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
    Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
    J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
    Doggrell SA
    Expert Opin Pharmacother; 2004 May; 5(5):1209-11. PubMed ID: 15155119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WITHDRAWN: Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks I; Macdonald R
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD003851. PubMed ID: 21901686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.